Navigation Links
Old drug may point the way to new treatments for diabetes and obesity
Date:2/10/2013

ANN ARBOR Researchers at the University of Michigan's Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice.

The findings from the lab of Alan Saltiel, the Mary Sue Coleman director of the Life Sciences Institute, are scheduled to be published online Feb. 10 in the journal Nature Medicine.

"One of the reasons that diets are so ineffective in producing weight loss for some people is that their bodies adjust to the reduced calories by also reducing their metabolism, so that they are 'defending' their body weight," Saltiel said. "Amlexanox seems to tweak the metabolic response to excessive calorie storage in mice."

Different formulations of amlexanox are currently prescribed to treat asthma in Japan and canker sores in the United States. Saltiel is teaming up with clinical-trial specialists at U-M to test whether amlexanox will be useful for treating obesity and diabetes in humans. He is also working with medicinal chemists at U-M to develop a new compound based on the drug that optimizes its formula.

The study appears to confirm and extend the notion that the genes IKKE and TBK1 play a crucial role for maintaining metabolic balance, a discovery published by the Saltiel lab in 2009 in the journal Cell.

"Amlexanox appears to work in mice by inhibiting two genesIKKE and TBK1that we think together act as a sort of brake on metabolism," Saltiel said. "By releasing the brake, amlexanox seems to free the metabolic system to burn more, and possibly store less, energy."

Using high-throughput chemical screening at LSI's Center for Chemical Genomics to search for compounds that inhibit IKKE and TBK1, the researchers hit upon an approved off-patent drug: amlexanox. They then demonstrated that amlexanox had profound beneficial effects in both genetic and dietary-induce
'/>"/>

Contact: Laura J. Williams
laurajw@umich.edu
734-615-4862
University of Michigan
Source:Eurekalert

Page: 1 2

Related biology news :

1. Bluemetal Architects appoints David Le Penske as Vice President of Health & Life Sciences
2. Summit of osteoporosis experts from CIS countries issue 5-point call for action
3. Scientists pinpoint molecular signals that make some women prone to miscarriage
4. Serendipity points to new potential target and therapy for melanoma
5. Research pinpoints key gene for regenerating cells after heart attack
6. Fish ear bones point to climate impacts
7. Protein injection points to muscular dystrophy treatment
8. University of Maryland School of Medicine, NIH study pinpoints brain areas role in learning
9. New study to examine ecological tipping points in hopes of preventing them
10. Fossil study helps pinpoint extinction risks for ocean animals
11. Remarkable enzyme points the way to reducing nitric acid use in industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... 2008) The Wildlife Conservation Society (WCS) recently launched ... affecting populations of a quintessential Arctic denizen: the rare ... Park Service, U. S. Geological Survey, and Alaska Fish ... six musk ox with GPS collars to better understand ...
... Health (CAMH) has discovered a new form of ... the eye defect retinitis pigmentosa (RP). CAMH also ... disorder, CC2D2A. This scientific advance will help ... brain development, and may help identify ways to ...
... research institutions in the U.S. and China has produced a ... out more than 90 percent of the plants gene coding ... And because it involves a genetically modified plant, the newly ... the genetic changes that make the plant resistant to the ...
Cached Biology News:New gene discovered for new form of intellectual disability 2First draft of transgenic papaya genome yields many fruits 2First draft of transgenic papaya genome yields many fruits 3
(Date:12/22/2014)... Dec. 22, 2014  Alternative Energy & Environmental ... has signed a letter of intent to acquire ... and patented a nanotechnology-based development platform used to ... enable rapid on-site collection and testing to identify ... issues in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/22/2014)... ITRA Global, one of the largest ... real estate, has further expanded its global reach with ... Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman of ... Global / ACORPP (Australian Corporate Property and Projects) , ... property services to a wide range of clients in ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... to design computer chips and electronic circuitry for extreme ... electrical engineers at Vanderbilt University has developed all the ... thin films of nanodiamond. They have created diamond versions ... a key element in computers., "Diamond-based devices have the ...
... Mass., Aug. 4, 2011 Interleukin Genetics, Inc. ... call and Webcast on Friday, August 12 at 9:30 a.m. ... To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 ... will be available on the Investors section of Interleukin Genetics, ...
... N.J., Aug. 4, 2011 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of AZD2820, a ... a single-agent therapy for the treatment of obesity. AZD2820 ... collaborative research program with Palatin Technologies. Obesity ...
Cached Biology Technology:Designing diamond circuits for extreme environments 2Designing diamond circuits for extreme environments 3Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Peptide-affinity Purified Polyclonal Antibody to Histamine H2 Receptor...
Biology Products: